SYDNEY, Australia--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented new findings from a phase 1b clinical trial of PRO 140 in individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS. At the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia, William C. Olson, Ph.D., Progenics’ Vice President, Research and Development, expanded upon top-line PRO 140 results announced in May 2007 in an oral presentation entitled, “Antiviral Effects and Tolerability of the CCR5 Monoclonal Antibody PRO 140: A Proof of Concept Study in HIV-Infected Individuals.” In addition to the clinical results presented for intravenously administered PRO 140, the Company also reported positive preclinical findings for a subcutaneous form of PRO 140 which will be advanced into clinical trials later this year. IAS plans to webcast this late-breaker-session presentation live, and the archive of the audio and accompanying slides of the presentation can be accessed at: www.ias2007.org/pag/PSession.aspx?s=151.
